The global immunocytokines market is expected to reach USD 5.3 billion in 2030 and anticipated to grow at a CAGR of 41% during the forecast period 2021-2030.

Cancer remains a significant global cause of mortality, claiming an estimated 0.6 million lives in the US alone in 2020. The World Health Organization foresees a staggering 70% surge in new cancer cases worldwide over the next two decades. Conventional treatments like chemotherapy, radiation therapy, and surgery, while commonly used, display limited efficacy, especially in advanced cancer stages. Moreover, their non-specific and highly toxic nature significantly compromises patients’ quality of life.

Emerging targeted anti-cancer therapies, particularly immunotherapy, have garnered attention for their ability to selectively target and eliminate tumor cells. Immunotherapeutic products, exemplified by immune checkpoint inhibitors such as atezolizumab, nivolumab, and pembrolizumab, demonstrate promising advantages with favorable side effect profiles, offering long-term clinical benefits to individuals with metastatic tumors. Innovative immunotherapies like dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells also hold potential in eradicating primary and metastatic cancer cells. However, these therapies entail risks, including severe and life-threatening side effects like cytokine storms. Additionally, T-cell therapies might result in detrimental biological effects due to mispairing of endogenous and transfected TCR ? and ? chains.

Cytokines have historically been explored in clinical trials as anti-cancer agents. Nevertheless, their systemic administration presents a range of dose-dependent side effects and unfavorable pharmacokinetic properties, limiting therapeutic dose escalation. To overcome these limitations, researchers are directing their attention toward immunocytokines?engineered fusion proteins that combine antibody target specificity with the immunological response capabilities of specific cytokines. These refined molecules exhibit enhanced efficacy and reduced toxicity compared to conventional cytokine-based therapies. Consequently, immunocytokines are under investigation for treating various conditions, including cancers, autoimmune disorders, and chronic inflammatory diseases. Notably, these emerging molecules display synergistic effects when combined with established therapeutics such as small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines.

Encouraged by promising clinical trial outcomes, this burgeoning domain is expected to witness substantial market growth. Pioneers in this field are poised to benefit from being the first to introduce these advancements to market.

Report Coverage

  • The report thoroughly examines the immunocytokines market, analyzing target indications, administration routes, and major geographical regions. It delves into market drivers, restraints, opportunities, and challenges impacting growth. Moreover, it evaluates both advantages and obstacles within the market landscape, providing insights into the competitive environment for top players. Revenue forecasts for market segments across different countries are included.
  • An in-depth analysis of the current market landscape concerning immunocytokines entails a comprehensive review from developmental phases of lead candidates, spanning discovery/preclinical stages to phase III trials. This evaluation categorizes therapy types?monotherapy and combination therapy?highlighting cytokine types (IL, IFN, TGF-?, TNF, and others) and antibody types (anti-CD20, anti-CEA, anti-CTLA-4, etc.). It also covers target disease indications, encompassing various categories like blood cancer, brain cancer, breast cancer, and more. Additionally, it considers the route of administration, including intravenous, intratumoral, subcutaneous, and other modes.
  • The report features detailed profiles of leading immunocytokine developers in a tabulated format, summarizing company details, financial data, product portfolios, recent advancements, and future assessments. It analyzes recent market developments, such as partnerships, clinical trials, licensing, mergers, acquisitions, and research collaborations. Moreover, it examines investments across developmental stages in companies focused on immunocytokine research.
  • A comprehensive review of completed, ongoing, and planned clinical studies of various immunocytokines considers parameters like trial registration year, development phase, patient population, study design, leading industry players, study focus, disease indications, and geographical regions.
  • Furthermore, the report compiles key opinion leaders (KOLs) within the immunocytokine market, evaluating their expertise based on involvement in clinical studies. This assessment considers their publications, citations, trial participation, affiliations, and professional network strength, utilizing data sources including platforms like LinkedIn.